For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

 

Member Resources


 

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

 

Image of medicine in pharmacy

 

Latest 340B Content

Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction against enforcement of state law protecting 340B pricing for contract pharmacy arrangements.
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.
340B Advocacy Alliance Bulletin
AHA 340B Advocacy Alliance for September 8, 2025.
Letter/Comment
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
340B Advocacy Alliance Bulletin
340B Advocacy Alliance Bulletin for September 5, 2025.
340B Advocacy Alliance Bulletin
340B Advocacy Alliance Bulletin for September 3, 2025.
Action Alert
Reps. Doris Matsui, D-Calif., Dusty Johnson, R-S.D., Debbie Dingell, D-Mich., and Tracey Mann, R-Kan., are circulating a “Dear Colleague” letter asking House members to sign a letter to the Department of Health and Human Services expressing concerns about the recently announced 340B Rebate Model Pilot Program.
Headline
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.
340B Advocacy Alliance Bulletin
AHA comments to HRSA on proposed 340B rebate model program; register for Aug. 28 AHA call to discuss rebate model.
Letter/Comment
AHA comments on the Health Resources and Services Administration’s notice of the 340B Rebate Model Pilot Program.